96 related articles for article (PubMed ID: 11195422)
1. Considerations in the management of myeloma.
Fishman MN; Dalton WS
Oncology (Williston Park); 2000 Nov; 14(11A):72-81. PubMed ID: 11195422
[TBL] [Abstract][Full Text] [Related]
2. [Management of multiple myeloma].
Di Raimondo F; Pennisi A; Bari A; Fiumara P; Palumbo GA
G Ital Nefrol; 2005; 22 Suppl 33():S46-52. PubMed ID: 16419006
[TBL] [Abstract][Full Text] [Related]
3. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
Klepin HD; Hurd DD
Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)].
Lokhorst H; Huijgens PC; Raymakers R; Bos GM; Vellenga E; Wijermans PW; Sonneveld P;
Ned Tijdschr Geneeskd; 2005 Apr; 149(15):808-13. PubMed ID: 15850271
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma: treatment options for an incurable disease.
Pandit SR
J Assoc Physicians India; 2005 Dec; 53():1060-4. PubMed ID: 16572964
[TBL] [Abstract][Full Text] [Related]
8. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma.
Gorschlüter M; Ziske C; Glasmacher A; Schmidt-Wolf IG
Clin Cancer Res; 2001 Aug; 7(8):2195-204. PubMed ID: 11489792
[TBL] [Abstract][Full Text] [Related]
9. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
10. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic.
Gibson J; Ho PJ; Joshua D
Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
13. Current role of immunotherapy in multiple myeloma.
Hájek R; Adam Z; Krivanová A; Doubek M; Korístek Z; Vorlícek J
Acta Med Austriaca; 1998; 25(3):79-85. PubMed ID: 9816399
[TBL] [Abstract][Full Text] [Related]
14. Management of multiple myeloma: the changing landscape.
Reece DE
Blood Rev; 2007 Nov; 21(6):301-14. PubMed ID: 17761373
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: charging toward a bright future.
Katzel JA; Hari P; Vesole DH
CA Cancer J Clin; 2007; 57(5):301-18. PubMed ID: 17855486
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
17. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
18. Stem-cell transplantation for multiple myeloma in the era of novel drugs.
Bensinger W
J Clin Oncol; 2008 Jan; 26(3):480-92. PubMed ID: 18056678
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
20. Role of allogeneic stem cell transplantation in multiple myeloma.
Bruno B; Giaccone L; Sorasio R; Boccadoro M
Semin Hematol; 2009 Apr; 46(2):158-65. PubMed ID: 19389499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
